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Abstract
Background: Colorectal cancer remains a major cause of cancer mortality in the Western world.
A limited number of studies  has been conducted in respect of Her-3 and Her-4 expression and
their correlation with  clinical parameters and prognosis in colorectal carcinomas . In this study we
sought to determine the pattern and the prognostic significance of HER-3 and HER-4 in colorectal
adenocarcinoma.
Methods: We studied HER-3 and HER-4 protein expression in106 paraffin embedded specimens
of primary colorectal tumors using immunohistochemistry. The pattern and protein expression
levels of HER-3 and HER-4 were correlated with several clinical and pathological parameters.
Results: HER-3 staining displayed membranous and cytoplasmic expression pattern in 18 (17%)
and 30 samples (28,3%), respectively. HER-4 membranous and cytoplasmic expression was found
in 20 (18,9%) and 32 samples (30,2%), respectively. Specimens regarded as positive for HER-3
cytoplasmic expression were associated with moderate tumor grade (p = 0,032) and older median
age (p = 0,010). Specimens regarded as positive for HER-4 membranous protein expression were
associated with involved lymphnodes (p = 0,0003). Similar results were obtained when considering
Her-3 and Her-4 protein expression irrespective of their cellular localization. There was no
correlation between the expression of HER-3 and HER-4 and patients outcome.
Conclusion: HER-4 membranous protein expression was found to predict for lymph nodes
positivity in this cohort of patients with colorectal cancer.HER-4 expression status may identify
tumors with aggressive biological behavior and increased metastatic potential.
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Background
Colorectal cancer remains a major cause of cancer mortal-
ity in the Western world both in men and women. It is the
second most common malignancy (13.1%) and the sec-
ond most common cause of cancer death in Europe[1].
The incidence of colorectal cancer has been increasing
worldwide rapidly over the past decades.
The stage of the disease is the most important factor pre-
dicting the treatment's outcome[2]. At presentation, 30%
of the patients have locally advanced cancer or metastatic
disease, which discourages surgical care. Even among
patients who undergo curative resection, approximately a
50% dies within five years. The role of adjuvant chemo-
therapy is clear in Dukes' C, but is controversial for Dukes'
B cancers[3]. Although TNM (tumor-nodes-metastasis)
classification is useful for staging patients and selecting
them for specific treatment, it is not sufficient, as many
patients at the same stage may have various outcomes.
Therefore, there is a great need to identify useful prognos-
tic markers to guide treatment decisions and/or to
develop more effective treatments.
The transmembrane receptors that have action as tyrosine
kinases play an important role in the pathogenesis of can-
cer in solid organs[4]. The type I receptor tyrosine kinase
family comprises four homologous members: erbB1
(EGFR or HER-1), erbB2 (HER-2/neu), erbB3 (HER-3)
and erbB4 (HER-4)[5].
The phosphorylation of these receptors through ligand
binding and homo- or hetero-dimerization activates a cas-
cade of signaling pathways that include: 1)the stress acti-
vated protein kinase pathway, involving protein kinase C
and Jak/Stat, 2) the ras-raf-mitogen activated protein
kinase pathway (MAP Kinase), 3) the protein serine/thre-
onine kinase Akt pathway. These routs regulate cellular
growth, differentiation, proliferation, angiogenesis and
apoptosis[6].
Ten genes have been identified to encode HER-ligands.
Out of these, the neuregulins(or heregulins) bind to HER-
3 and HER-4 while betacellulin, epiregulin and heparin-
binding EGF bind to HER-4[7].
HER-3 gene is located on chromosome 12q13 and
encodes a 160 KDa transmembrane glycoprotein, that has
no functional kinase domain and requires the dimeriza-
tion with another receptor to activate downstream signal
transduction pathways[8]. It's found to be overexpressed
in various organs including breast, lung, pancreas and
stomach. HER-4 gene is located on chromosome 2q33.3–
34 and encodes a 180 KDa transmembrane glycopro-
tein[9]. HER-4 plays a crucial role in several important
pathological processes – such as malignancy and heart
disease – and in the development and differentiation of
various tissues, especially cardiovascular, neural system
and mammary glands[10].
There is limited data regarding the prognostic role of HER-
3 and HER-4 in human cancer and these prove to be con-
troversial. Some reports associate their overexpression
with short while others with longer survival, thus,
extended studies are required to ascertain definitively
their prognostic value [11-13]. A limited number of stud-
ies has been conducted in respect of Her-3 and Her-4
expression and their correlation with clinical parameters
and prognosis in colorectal carcinomas. Little therefore is
known about their role in the pathogenesis of colorectal
cancer. This study was conducted in order to investigate
the immunohistochemical expression of Her-3 and Her-4
in colorectal carcinoma, to clarify their role in the progno-
sis of these carcinomas and to investigate the possible cor-
relation with various clinical and pathological
parameters.
Methods
Patients and tumor specimens
One hundred and six (106) formalin fixed and paraffin
embedded colorectal cancer specimens, diagnosed at the
Pathology Department of Evangelismos Hospital in Ath-
ens from 1997 to 2003, were studied. These specimens
were collected from patients treated at the Oncology Unit
of the Second Department of Internal Medicine – Propae-
deutic, University of Athens. The clinical information of
these patients derives from the medical records of the
Department. Among the 106 patients, 103 had undergone
surgical resection of the tumor; the remaining 3 patient's
diagnosis was established by colonoscopy and consecu-
tive biopsy. The evaluation of the 3 patients' preoperative
imaging revealed metastasis. Since no surgery was per-
formed, no information about the tumor size and the sta-
tus of lymph nodes was available. None of the 106
patients had received chemotherapy or radiation therapy
prior to surgery or died in the peri- or post-operative time
period (within 45 days after surgery). The patients were
staged using the Astler Coller – modified Dukes system.
There were 30 patients (28.3%) with Dukes B, 51 patients
(48.1%) with Dukes C and 25 patients (23.6%) with
Dukes D. Dukes A patients were not included in the study
since they received no further treatment. Postoperative
chemotherapy with irinotecan, leucovorin and 5-fluorou-
racil (IFL) was administered to the whole group of
patients. Although there is controversy concerning the
role of adjuvant IFL chemotherapy in Dukes' B and Dukes'
C cancers, the selected treatment was part of an adjuvant
protocol or as first line treatment for metastatic disease of
the Hellenic Cooperative Oncology Group (HECOG).
Informed consent was obtained from all the patients and
the protocol was approved by Attikon university hospitalBMC Cancer 2006, 6:46 http://www.biomedcentral.com/1471-2407/6/46
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ethics commitee. All patients received regular follow-ups
and survival data as of March 2005 were ascertained
through the patients' records. The median duration of the
follow-ups was 31 months (range 7–125 months).
Immunohistochemistry
All the available hematoxylin and eosin stained slides of
surgical specimens were reviewed and representative par-
affin blocks for each case were selected for immunohisto-
chemical study. Two serial sections of 4 µm thick were cut
from each block and placed onto Super Frost Plus glass-
slides. Following deparaffinization in xylene, the slides
were rehydrated and washed in Tris Buffered Saline (TBS).
The endogenous peroxidase activity was quenched by 10
min incubation in a mixture of 3% hydrogen peroxide
solution in 100% methanol (Sigma). Slides were cleared
with TBS and placed at room temperature for 1 hour. They
were then incubated with monoclonal mouse antibody to
human Her-3 protein (MAb-MsS-725-P, Neomarkers, Fre-
mont, CA) at 1/35 dilution and with monoclonal mouse
antibody to human Her-4 protein (Ab-4, HFR-1, Neomar-
kers, Fremont, CA) at 1/100 dilution overnight at +4°C.
Slides were washed three times in TBS. The signal was vis-
ualized using the DAKO-EnVision Kit (k 5007 HRP Rab-
bit/Mouse DAB+) for 60 min. After washing with TBS,
slides were kept in diaminobenzidine tetrahydrochloride
for 7 min then counterstained with Mayers hematoxylin.
Sections of breast carcinoma and striated muscle were
used as positive controls. Slides were treated as negative
controls by omitting the primary antibody.
Scoring system
Sections were examined using light microscopy by two
independent observers (K.P. and D.R) who were unaware
of the clinicopathological data. Interobserver variation
was resolved by simultaneous dual re-evaluation. Both
membranous and cytoplasmic immunostaining was eval-
uated semiquantitatively.
Membranous staining was considered positive (+) when
more than 1% of tumor cells were stained, irrespective of
whether the staining pattern was complete circumferential
or not (Fig. 1). When less than 1% of tumor cells were
stained it was considered negative (-).Cytoplasmic stain-
ing was scored as 0, no staining or weak staining in <10%
of tumor cells; 1+, weak immunostaining in >10% of
tumor cells; 2+, moderate immunostaining in >10% of
tumor cells and 3+, strong immunostaining in >10% of
tumor cells. Staining pattern was either granular or diffuse
(Fig. 2). Scores of 0 and 1+ indicate a negative tumor,
while scores of 2+ and 3+ were regarded as positive.
Tumors were considered positive for both, membranous
and cytoplasmic staining by using the above mentioned
criteria, irrespective of whether the expression of the anti-
bodies was localized in the same cell or in different groups
of tumor cells (Fig. 3).
Statistical analysis
Categorical characteristics were summarized as percent-
ages and their association with HER-3 and HER-4 overex-
pression was assessed using the Pearson χ2 test or the
Fisher exact test[14]. Continuous characteristics compari-
sons were performed using the Mann- Whitney test. The
probability of survival was calculated by the Kaplan-
Positive diffused and granular exclusively cytoplasmic staining  for HER-4 (x400) Figure 2
Positive diffused and granular exclusively cytoplasmic staining 
for HER-4 (x400)
HER-3 strong membranous and weak to moderate cytoplas- mic staining (× 200) Figure 1
HER-3 strong membranous and weak to moderate cytoplas-
mic staining (× 200).BMC Cancer 2006, 6:46 http://www.biomedcentral.com/1471-2407/6/46
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Meier method and differences in survival were assessed by
the log- rank test[15]. All statistical tests were performed
on a = 0.05 level of significance. Analysis was performed
using SPSS 11.0.1 for windows.
Results
One hundred and six (106) colon carcinomas samples
were examined. Sixty six patients were males (62.3%) and
forty patients were females (37.7%). The median age of
the patients was 63 years (35- 79 years). Patients' median
follow up time was 31 months (7- 125 months). In this
period of time, 33 deaths and 38 relapses were observed.
The 3-year survival rate was 72.4%, and the 5-year survival
rate was 45.7%.
Eighteen samples (17%) out of one hundred and six were
evaluated as positive for HER-3 membranous protein
expression. Cytoplasmic staining for HER-3 was evaluated
as follows: 39 specimens (36,8%) were negative for HER-
3 expression,37 (34,9 %) were scored as 1+, 20 (18,9%)
were scored as 2+, while 10 (9,4%)were scored as 3+.
Scores of 2+ and 3+ were regarded as positive expression.
Twenty samples (18,9%) were positive for HER-4 mem-
branous protein expression. Cytoplasmic staining for
HER-4 was evaluated as follows:32 samples (30,2%) were
negative for HER-4 expression,42 (39,6%) were scored as
1+, 29 (27,4%) were scored as 2+, while 3 (2,8%) were
scored as 3+. Scores of 2+ and 3+ were regarded as positive
expression.
When considering Her-3 and Her-4 protein expression as
positive irrespective of the cellular localization, 37 speci-
mens (34.9%) were found to be positive for Her-3 and 40
specimens (37.7%) positive for Her-4.
Statistical analysis revealed no relationship between
membranous Her-3 protein expression and any of the
clinicopathological parameters under evaluation (Table
1). Patients regarded as negative for HER-3 cytoplasmic
expression had smaller median age than those with posi-
tive HER-3 cytoplasmic expression (61 versus 66 years, p
= 0,010). All the patients regarded as positive for HER-3
cytoplasmic expression, had moderately differentiated
tumors (p = 0,032) (Table 1).
The majority of positive samples for HER-4 membranous
protein expression (95%) were associated with involved
lymph nodes (p = 0,0003). Patients regarded as negative
for HER-4 membranous expression were associated with
Dukes' stage B (p = 0.010) (Table 2). There was no associ-
ation between HER-4 cytoplasmic protein expression and
any clinicopathological parameter (Table 2).
For tumors that were considered as positive irrespective of
the cellular localization of each marker, statistical analysis
revealed that Her-3 expression was associated with an
older median age group (p = 0.009) and with moderately
and poorly differentiated tumors (p = 0.008 and p = 0.048
respectively). Her-4 positivity was related with involved
lymphnodes (p = 0.010) (Table 3). There was no associa-
tion with patients' survival as analysed by Kaplan Meier's
curves (data non shown).
Membranous or cytoplasmic expression of HER-3 and
HER-4 was not associated with patients' survival as ana-
lysed by Kaplan Meier's curves (Figures 4, 5, 6, 7). Coex-
pression for HER -3 and HER-4 was observed in 3 out of
106 cases (2,8%) with membranous staining (k = 0.025,
p = 0,793) and in 15 out of 106 cases (14,2%) with cyto-
plasmic staining (k = 0.271, p = 0,005). There was no sta-
tistically significant difference in patients characteristics or
overall survival with respect to Her-3 and Her-4 coexpres-
sion as compared to the expression of each antibody
alone.
Discussion
Colorectal malignancies remain one of the major causes
of cancer death. The last decade newer cytotoxic agents
such as oxaliplatin and irinotecan have shown promise in
the adjuvant setting. The administration of these agents
has increased the overall survival rate as well as the time
to progression in patients with metastatic cancer[16,17].
Despite significant improvements in traditional chemo-
therapy regimens, over the last years, the main efforts of
research have focused on the use of targeted therapy.
>Complete circumferential membranous staining of HER-3  as opposed to the absence of immunoreaction in the adeno- matous part of lesion (× 200) Figure 3
Complete circumferential membranous staining of HER-3 as 
opposed to the absence of immunoreaction in the adenoma-
tous part of lesion (× 200)BMC Cancer 2006, 6:46 http://www.biomedcentral.com/1471-2407/6/46
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The low molecular weight tyrosine kinase inhibitors and
the monoclonal antibodies against EGFR are in clinical
development[18,19]. These strategies have shown prom-
ise; more efforts focus on the identification of new molec-
ular prognostic markers and the development of
molecular targeted therapies against colorectal cancer.
The type I tyrosine kinase receptors and the associated sig-
nal transduction pathways have a crucial role in cancer
Table 2: Patient clinicopathological data and HER-4 membranous and cytoplasmic expression
HER-4 membranous expression HER-4 cytoplasmic expression
Characteristic (+) (n= 20) (-) (n= 86) p (+) (n = 32) (-) (n= 74) P
Age Median (range) 64 (40 – 75) 63 (35 – 79) 0.906 64 (40 – 76) 63 (35 – 79) 0.656
Sex
Male 13 (65.0%) 53 (61.6%) 0.779 20 (62.5%) 46 (62.2%) 0.974
Female 7 (35.0%) 33 (38.4%) 12 (37.5%) 28 (37.8%)
Size 5 (1.6 – 8.5) 5 (1.5 – 12) 0.383 5 (2 – 10) 5 (1.5 – 12) 0.128
Lymph nodes status
(+) 19 (26.8%) 50 (60.2%) 0.003 25 (78.1%) 44 (62.0%) 0.107
(-) 1 (5.0%) 33 (39.8%) 7 (21.9%) 27 (38.0%)
Grade
Well - 3 (3.5%) 0.999 - 3 (4.1%) 0.552
Moderate 17 (85.0%) 78 (90.7%) 0.431 31 (96.9%) 64 (86.5%) 0.167
Poor 3 (15.0%) 5 (5.8%) 0.171 1 (3.1%) 7 (9.5%) 0.430
Dukes' stage
B 1 (5.0%) 29 (33.7%) 0.010 7 (21.9%) 23 (31.1%) 0.334
C 11 (55.0%) 40 (46.5%) 0.494 14 (43.8%) 37 (50.0%) 0.554
D 8 (40.0%) 17 (19.8%) 0.078 11 (44.4%) 14 (18.9%) 0.085
Site
Proximal colon 4 (20.0%) 25 (29.1%) 0.412 11 (34.4%) 18 (24.3%) 0.287
Distal colon 9 (45.0%) 28 (75.7%) 0.293 11 (34.4%) 26 (35.1%) 0.940
Rectum 7 (61.6%) 33 (38.4%) 0.779 10 (31.2%) 30 (40.5%) 0.365
Table 1: Patient clinicopathological data and HER-3 membranous and cytoplasmic expression
HER-3 membranous expression HER-3 cytoplasmic expression
Characteristic (+) (n= 18) (-) (n= 88) p (+) (n= 30) (-) (n= 76) P
Age Median (range) 68 (53 – 75) 63 (35 – 79) 0.069 66 (52 – 76) 61 (35 – 79) 0.010
Sex
Male 10 (55.6%) 56(63.6%) 0.519 15 (50.0%) 51 (67.1%) 0.112
Female 8 (44.4%) 32(36.4%) 15 (50.0%) 25 (32.9%)
Size 5 (2 – 12) 5 (1.5 – 12) 0.959 5 (2 – 10) 5 (1.5 – 12) 0.525
Lymph nodes status
(+) 13 (72.2%) 56(65.9%) 0.603 20 (66.7%) 49 (67.1%) 0.964
(-) 5 (27.8%) 29(34.1%) 10 (33.3%) 24 (32.9%)
Grade
Well - 3 (3.4%) 0.999 - 3 (3.9%) 0.556
Moderate 18 (100%) 77(87.5%) 0.205 30 (100.0%) 65 (85.5%) 0.032
Poor - 8 (18%) 0.346 - 8 (10.5%) 0.101
Dukes' stage
B 4 (22.2%) 26(29.5%) 0.530 9 (30.0%) 21 (27.6%) 0.807
C 11 (61.1%) 40(45.5%) 0.226 14 (46.7%) 37 (48.7%) 0.851
D 3 (16.7%) 22(25.0%) 0.448 7 (23.3%) 18 (23.7%) 0.969
Site
Proximal colon 4 (22.2%) 25(28.4%) 0.774 7 (23.3%) 22 (28.9%) 0.534
Distal colon 9 (50.0%) 28(31.8%) 0.140 10 (33.3%) 27 (35.5%) 0.796
Rectum 5 (27.8%) 35(39.8%) 0.339 13 (43.3%) 27 (35.5%) 0.406BMC Cancer 2006, 6:46 http://www.biomedcentral.com/1471-2407/6/46
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biology and are attractive targets for cancer therapy. Out
of the four members of the type I receptor tyrosine kinase
family, EGFR and Her-2 have been widely studied on sev-
eral human tumors, mostly breast and colon carcinoma.
In most studies their protein expression as evaluated by
immunohistochemical techniques was found to be
related to poor prognostic factors[20,21]. On the contrary
the role of Her-3 and Her-4 in the pathobiology of carci-
nomas has not yet been clarified. Most of the studies were
conducted on breast carcinomas and the results have
Kaplan Meier curves for the overall survival of patients with  positive (continuous line) and negative (dotted line) HER-4  membranous expression Figure 5
Kaplan Meier curves for the overall survival of patients with 
positive (continuous line) and negative (dotted line) HER-4 
membranous expression.
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Table 3: Patient clinicopathological data and HER-3, HER-4 expression
HER- 3 expression (membranous or cytoplasmic) HER- 4 expression (membranous or cytoplasmic)
Characteristic (+) (n= 37) (-) (n= 69) p (+) (n= 40) (-) (n= 66) p
Age Median 
(range)
65 (52 – 76) 61 (35 – 79) 0.009 64.5 (40 – 76) 61 (35 – 79) 0.189
Sex
Male 19 (51.4%) 47 (68.1%) 0.098 24 (60%) 42 (63.6%) 0.836
Female 18 (48.6%) 22 (31.9%) 16 (40%) 24 (36.4%)
Size 5 (2 – 12) 5 (1.5 – 12) 0.425 5 (2 – 12) 5 (1.5 – 12) 0.195
Lymph nodes status
(+) 25 (67.6%) 44 (63.8%) 0.999 33 (82.5%) 36 (54.5%) 0.010
(-) 12 (32.4%) 22 (31.9%) 7 (17.5%) 27 (40.9%)
Grade
Well - 3 (4.2%) 0.550 - 3 (4.5%) 0.288
Moderate 37 (100%) 58 (84.1%) 0.008 37 (92.5%) 58 (87.9%) 0.529
Poor - 8 (11.6%) 0.048 3 (7.5%) 5 (7.6%) 0.999
Dukes' stage
B 11 (29.7%) 19 (27.5%) 0.824 7 (17.5%) 23 (34.8%) 0.075
C 18 (48.6%) 33 (47.8%) 0.999 20 (50%) 31 (47%) 0.842
D 8 (21.6%) 17 (24.6%) 0.813 13 (32.5%) 12 (18.2%) 0.104
Site
Proximal colon 10 (27%) 19 (27.5%) 0.999 12 (30%) 17 (25.8%) 0.658
Distal colon 13 (35.1%) 24 (34.8%) 0.999 14 (35%) 23 (34.8%) 0.999
Rectum 14 (37.8%) 26 (37.7%) 0.999 26 (39.4%) 14 (35%) 0.684
Proximal colon:cecum, ascending, transverse colon. Distal colon:descending, sigmoid colon
Kaplan Meier curves for the overall survival of patients with  positive (continuous line) and negative (dotted line) HER-3  membranous expression Figure 4
Kaplan Meier curves for the overall survival of patients with 
positive (continuous line) and negative (dotted line) HER-3 
membranous expression.
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proven to be controversial. Most investigators revealed
that HER-3 protein expression on breast carcinomas was
associated with poor prognostic factors such as large
tumor size, high grade of malignancy and lymph node
metastasis[22,23]. However, others have found that HER-
3 expression was associated with an improved 10- year
survival as well as estrogen receptor (ER) positivity, which
is a favorable prognostic factor for breast cancer[24]. HER-
4 protein overexpression on breast carcinomas was associ-
ated in several studies with the longer survival of patients,
ER positivity, low proliferation rate and low probability of
recurrence, while other studies have correlated HER-4
overexpression with negative prognostic factors [25-27].
Results in human breast cancer cell lines are also conflict-
ing (28,29).
In colorectal cancer, only a few studies have investigated
the protein expression of Her-3 and Her-4. From the
obtained data, the incidence of HER-3 expression in color-
ectal cancer ranges from 36 % to 89 % (30, 31). Poller et
al. (32) revealed a 88,8% positive rate for HER-3 expres-
sion, both mebranous and cytoplasmic. Rajkumar et al.
(33) detected a 68,75 % rate for HER-3 expression, pre-
dominantly cytoplasmic. Maurer and co-workers (31)
demonstrated that HER-3 is expressed in 89 % in primary
colorectal carcinomas and the immunoreactivity was both
membranous and cytoplasmic. Kapitanovic et al.(34)
revealed a 78 % rate for HER-3 expression, which was
exclusively cytoplasmic. Lee et al.(30) detected a 36 % rate
for membranous HER-3 expression and a 22 % rate for
membranous HER-4 expression. To the best of our knowl-
edge this was the only study conducted on Her-4 protein
expression in colon carcinoma
In our study, both membranous and cytoplasmic Her-3
and Her-4 protein expression was identified. The rates of
expression for Her-3 and Her-4 respectively were as fol-
lows: 17% membranous, 28.3 % cytoplasmic and 18.9%
membranous, 30.2% cytoplasmic. Both membranous and
cytoplasmic staining was found in 11.3% of Her-3 and
14.1% of Her-4 positive cases. As opposed to the five stud-
ies already mentioned, we evaluated protein expression
not only irrespective of the cellular localization of the
antibody but also on different cellular compartment
(membrane or cytoplasm) separately, assuming that this
phenomenon might be related to divergent functional
properties of the genes.
In their study, Maurer et al.(31) suggested a growth-
enhancing role of Her-3 in colorectal cancer. They specu-
lated that extreme Her-3 immunostaining was associated
with tumors presenting mucus production, which is a sign
of advanced tumor disease. Overexpression of Her-3 was
also found in the invading edge of the tumor as well as in
the transition zone between adenomatous and cancerous
tissue (Fig. 3). These findings were considered to indicate
the role of Her-3 in tumor progression. Moreover, Kapi-
tanovic et al.(34) revealed that patients regarded as nega-
tive for HER-3 expression survived significantly longer
than patients with HER-3 expression (p < 0.05). On the
Kaplan Meier curves for the overall survival of patients with  positive (continuous line) and negative (dotted line) HER-4  cytoplasmic expression Figure 7
Kaplan Meier curves for the overall survival of patients with 
positive (continuous line) and negative (dotted line) HER-4 
cytoplasmic expression.
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Kaplan Meier curves for the overall survival of patients with  positive (continuous line) and negative (dotted line) HER-3  cytoplasmic expression Figure 6
Kaplan Meier curves for the overall survival of patients with 
positive (continuous line) and negative (dotted line) HER-3 
cytoplasmic expression.
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other hand, the results of Lee et al.(30) demonstrated that
HER-3 overexpression was correlated with patients in the
early stages of the disease (p < 0.0001). In our study, Her-
3 membranous expression was not related to any of the
clinicopathological parameters under evaluation while
positive cytoplasmic Her-3 protein expression was found
mostly in moderately differentiated tumors(p = 0.032)
and in the older age group (p = 0.010). When cases with
both membranous and cytoplasmic staining were consid-
ered as positive, then also poorly differentiated tumors (p
= 0.048) were found to have a statistical significant over-
expression of Her-3 protein. Due to the small number of
cases (3 highly differentiated – 8 poorly differentiated)
these findings are not sufficient to support any possible
role of Her-3 in tumor progression.
Regarding Her-4 protein expression on colorectal cancer,
only Lee et al have recently conducted a detailed study. In
their series, 22% of the cases showed membranous over-
expression of Her-4. This incidence tended to be higher in
later stage than in early stage cancers. This is in accordance
with our observations. In our study, the majority of posi-
tive samples for HER-4 membranous protein expression
(95%) were associated with involved lymph nodes (p =
0,0003). The same results were obtained when cases with
both membranous and cytoplasmic expression of Her-4
were considered as positive (p = 0.010). Patients who
tested negative for HER-4 membranous expression were
associated with Dukes' stage B cancer (p = 0.010).
The coexpression of both Her-3 and Her-4 membranous
and cytoplasmic immunostaining for each marker sepa-
rately was not found to be related to any clinicopatholog-
ical parameter.
Conclusion
Our findings do not support any major role between Her-
3 protein expression and tumor biology in colon carci-
noma. Judging from the two existing studies on Her-4, the
study of Lee et. al (30) and our own, there is strong evi-
dence that Her-4 membranous protein expression in
colon carcinoma, might indicate at tumors with more
aggressive biological behavior. If this proves to be right,
then some patients could be favored from the administra-
tion of pan-Her inhibitors. Certainly, our relatively small
sample may not have been enough to detect differences.
Larger studies with extended follow-ups will be required
to ascertain the prognostic value of Her-3 and Her-4
expression in colorectal carcinomas. Moreover, in this
study, only HER-3, HER-4 part of the signaling system was
evaluated. Estimating the expression of all four members
of the Her family as well as of an array of receptor-specific
ligands would probably give more information on some
steps of the signal transduction pathway and on the clini-
cal significance of the interactions between the different
receptors.
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